Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

(2013) Ali T. Taher et al.   AMERICAN JOURNAL OF HEMATOLOGY

Iron overload in β-thalassemia intermedia

(2013) Khaled M. Musallam et al.   CURRENT OPINION IN HEMATOLOGY

Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials

(2011) Aurelio Maggio et al.   BLOOD CELLS MOLECULES AND DISEASES

Elevated liver iron concentration is a marker of increased morbidity in patients with   thalassemia intermedia

(2011) K. M. Musallam et al.   HAEMATOLOGICA

Anemia, Ineffective Erythropoiesis, and Hepcidin: Interacting Factors in Abnormal Iron Metabolism Leading to Iron Overload in β-Thalassemia

(2010) Sara Gardenghi et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia

(2009) Ali Taher et al.   BRITISH JOURNAL OF HAEMATOLOGY

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

(2009) Kallistheni Farmaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major

(2009) Casey J. Brewer et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Inflammation and oxidant-stress in  -thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial

(2008) P. B. Walter et al.   HAEMATOLOGICA